Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients

Kaiser Permanente55 enrolled

Overview

Transition to Ferric Citrate among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study from Kaiser Permanente Southern California

PROTOCOL SUMMARY Title: Transition to Ferric Citrate among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study from Kaiser Permanente Southern California Short Title: FeCitrate Protocol Number: KP FeCitrate Study Phase: 4 Study Site(s): Los Angeles Kaiser Sunset Medical Center Number of Subjects: 55 Study Arms: 1 Indication: Hyperphosphatemia in end stage renal disease Primary Purpose: To evaluate the efficacy of ferric citrate for control of serum phosphorus levels and maintenance of adequate iron stores among dialysis-dependent patients before and after conversion from traditional phosphate binders in a "real world" environment Overview of Study Design: Prospective non-randomized cohort study of 6-9 months duration (active study period 6 months). Investigational Product Administration: One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption. Study Endpoint: Mean serum phosphorus levels and rate of successful phosphorus control (\<5.5mg/dl) 6 months before and after treatment with ferric citrate Statistical Methods: Not powered to detect statistical significance

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Hyperphosphatemia

Interventions

Ferric CitrateDRUG

One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Currently using 3 to 18 pills per day of calcium acetate, sevelamer, lanthanum, or calcium carbonate * Mean serum phosphorus 4.0-\<8.0 mg/dl for 6 months prior to enrollment * No allergy to iron * Mean corrected serum calcium \> 8.0 mg/dl for 6 months prior to enrollment * Mean PTH \< 1000 pg/ml for 6 months prior to enrollment * Mean ferritin \< 1500 ng/ml and mean iron sat \< 50% for 6 months prior to enrollment Exclusion Criteria: * History of gastrointestinal bleeding within past 6 months * History of hospitalization for gastroparesis, bowel obstruction, or abdominal surgery within past 6 months * Acute kidney injury equal to or less than 3 months before the initial screening date * Active malignancy * Functioning renal transplant * Patients with iron overload syndrome (e.g., Hemochromatosis) * History autoimmune disease, hemoglobinopathy, hemochromatosis, sickle cell disease * Active or past history of calciphylaxis

Locations (1)

Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, United States

Outcomes

Primary Outcomes

Phosphorus Levels

Serum phosphorus levels measured by mg/dL from the 6 months prior to enrollment were compared to serum phosphorus levels collected during the 6 months of ferric citrate use

Time frame: 6 months

Secondary Outcomes

Intravenous (IV) Iron

The amount of intravenous (IV) iron in mg used per month by participants for 6 months before and 6 months on Ferric Citrate treatment.

Time frame: 6 months

Erythropoiesis Stimulating Agents (ESA) Dose

Mean Erythropoiesis Stimulating Agents (ESA) use from the 6 months prior to enrollment were compared to ESA use during the 6 months of ferric citrate use. The mean ESA dose units given to each participant per month was used in the analysis of this outcome.

Time frame: 6 months

Median Pill Count

median pill count of ferric citrate pills/day required to maintain phosphorus control

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.